Complete Genome Sequence of the Oncolytic Sendai virus Strain Moscow-Reference-Cited by-同舟云学术

Complete Genome Sequence of the Oncolytic Sendai virus Strain Moscow

Published:2016-08-25 Issue:4 Volume:4 Page:
ISSN:2169-8287
Container-title:Genome Announcements
language:en
Short-container-title:Genome Announc

Author:

Zainutdinov Sergei S.¹²,Tikunov Artem Y.¹³,Matveeva Olga V.⁴,Netesov Sergei V.¹,Kochneva Galina V.²

Affiliation:

1. Novosibirsk State University, Novosibirsk, Russia

2. State Research Center of Virology and Biotechnology Vector, Koltsovo, Novosibirsk Region, Russia

3. Institute of Chemical Biology and Fundamental Medicine of SB RAS, Novosibirsk, Russia

4. Biopolymer Design LLC, Acton, Massachusetts, USA

Abstract

ABSTRACT We report here the complete genome sequence of Sendai virus Moscow strain. Anecdotal evidence for the efficacy of oncolytic virotherapy exists for this strain. The RNA genome of the Moscow strain is 15,384 nucleotides in length and differs from the nearest strain, BB1, by 18 nucleotides and 11 amino acids.

Funder

Novosibirsk State University

Publisher

American Society for Microbiology

Subject

Genetics,Molecular Biology

Link

https://journals.asm.org/doi/pdf/10.1128/genomeA.00818-16

Reference6 articles.

1. Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency

2. Oncolysis by paramyxoviruses: preclinical and clinical studies

3. Mechanisms of Oncolysis by Paramyxovirus Sendai

4. Shortening by Actinomycin D of Latent Period of Multiplication of Sendai Virus

5. Senin V Senina A Matveeva O. 2014. Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus. Russian Federation patent N 2519763.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and Protective Efficacy of a Single Intranasal Dose Vectored Vaccine Based on Sendai Virus (Moscow Strain) against SARS-CoV-2 Variant of Concern;Vaccines;2024-07-16

2. Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae: <i>Respirovirus</i>) strain Moscow;Problems of Virology;2023-07-06

3. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes;Viruses;2021-06-29

Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes

;Oncolytic Virotherapy;2019-07

5. Change in Oncolytic Activity of Sendai Virus during Adaptation to Cell Cultures;Molecular Genetics, Microbiology and Virology;2017-10